Navigation Links
WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
Date:6/10/2008

SHANGHAI, China, June 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has signed a new three-year collaboration agreement with AstraZeneca.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

In April 2006, WuXi PharmaTech and AstraZeneca entered into a two-year US$14 million collaboration agreement that WuXi PharmaTech successfully delivered more than 100,000 compounds two months ahead of schedule.

"This new collaboration agreement further strengthens our already productive relationship with AstraZeneca, and it is the direct result of our research capability and firm commitment to quality and customer satisfaction," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, "We are hopeful that with our strong and growing drug R&D capabilities the expansion of our collaboration will help AstraZeneca achieve its strategic goals."

Under the new collaboration agreement WuXi PharmaTech will synthesize compounds, according to AstraZeneca's designs, which will further expand AstraZeneca's global compound collection.

"The collaboration with WuXi PharmaTech has exceeded our expectations delivering value to AstraZeneca beyond the cost savings in labor and materials," said Deborah Hartman, Vice President, Lead Generation Discovery Enabling Capabilities and Sciences (DECS), AstraZeneca, "We are looking forward to the prospect of building on this success through our expanded relationship."

High Throughput Screening remains a major source of chemical starting points, making it important to generate many high quality compounds with the proper purity and targeted characteristics. WuXi PharmaTech has developed an innovative, scalable and hi
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
2. WuXi PharmaTech Announces First Quarter 2008 Results
3. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
4. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
5. WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
6. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
7. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
8. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
9. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
10. WuXi PharmaTech Completes Acquisition of AppTec
11. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... WI (PRWEB) January 22, 2015 Dr. Greg ... the 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics ... Conference is an annual continuing education conference for health care ... and included the topic of probiotics in health. Dr. Leyer ...
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
(Date:12/24/2014)... GMO corn cases filed across the United ... process of being consolidated in a Kansas federal court for ... MIR 162 Corn Litigation, MDL No. 2591 in the U.S. ... the Syngenta GMO corn multidistrict litigation (MDL) has been handed ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... , , Honorees ... to be recognized at Sept. 30 gala ceremony , ... Prix Galien USA will recognize innovative biopharmaceutical drugs and medical technologies ... life at a gala event on September 30. Candidates for the ...
... ALBANY, Ore., Aug. 6 Synthetech, Inc. (OTC Bulletin Board: ... 2010, which ended June 30, 2009. Revenue for the quarter ... million in the first quarter of fiscal 2009. Operating income ... of $314,000 for the same period last year. Net income ...
... , , ST. ... ) today announced the acquisition of cheminformatics company, ChemNavigator(R).com, ... tools used for design, selection and procurement of chemical ... ) comprehensive suite of virtual screening and selection ...
Cached Biology Technology:Prix Galien USA Announces 2009 Final Candidates 2Synthetech Reports First Quarter Fiscal 2010 Results 2Synthetech Reports First Quarter Fiscal 2010 Results 3Synthetech Reports First Quarter Fiscal 2010 Results 4Synthetech Reports First Quarter Fiscal 2010 Results 5Synthetech Reports First Quarter Fiscal 2010 Results 6Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services 2Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services 3
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... http://photos.prnewswire.com/prnh/20130307/600769 ... introduced the fingerprint reading feature with the iPhone 5S. ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading personal genetics ... fine-scale differences in genetic ancestry of individuals from across ... first arrived more than four hundred years ago, ... place for peoples from different continents. This study illuminates how ...
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 Based on ... Samsung introduces for the first time a fingerprint sensor ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... temperatures in the Northeast Shelf Large Marine Ecosystem during ... to the latest Ecosystem Advisory issued by NOAA,s Northeast ... (SSTs) are the latest in a trend of above ... and part of a pattern of elevated temperatures occurring ...
... Proteins, unlike diamonds, aren,t forever. And when they wear ... back into amino acids, where they will be recycled ... Howard Hughes Medical Institute have identified a new way ... of unwanted and potentially toxic proteins, a finding that ...
... , April 26, 2013  Xencor announced today that MorphoSys AG ... trial of MOR208 in B-cell acute lymphoblastic leukemia (B-ALL). MOR208 ... cytotoxic function for which MorphoSys licensed exclusive worldwide rights from ... the study triggers an undisclosed milestone payment to Xencor. ...
Cached Biology News:Sea surface temperatures reach highest level in 150 years 2Sea surface temperatures reach highest level in 150 years 3Scientists discover new way protein degradation is regulated 2Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia 2
... Direct In Situ Apoptosis Detection ... situ by the direct TUNEL ... tagged with a directly labeled ... fluorescence staining for 40 samples ...
... The CHEMICON APO-BRDU Kit is ... DNA breaks and total cellular DNA to ... The kit contains the instructions and reagents ... positive and negative control cells for assessing ...
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
... latest entry in the Biomek line. With an,up-to-date ... robustness, it can meet the needs of just ... either one or two pipetting pods. With its ... standard for flexible laboratory solutions to meet your ...
Biology Products: